Premal Patel, MD, PhD

Premal Patel has extensive experience in drug development and running executive teams at leading companies. Most recently, Premal was the CMO at eFFECTOR Therapeutics, where he redefined the clinical strategy and helped lead a successful IPO. Premal has led next generation CAR-T cell therapy at premier companies including: 1) Lyell Immunopharma as CMO; 2) SVP, Head of Early Clinical Development at Juno Therapeutics; 3) VP, Head Early Clinical Development and Translational Research at Pfizer where he led the allogenic CAR-T effort and ~15 immuno-oncology assets. These efforts helped lead to formation of Allogene, acquisition of Juno by Celgene, and IPO of Lyell. Prior, he spent over 7 years at Genentech, Research and Early Development leading clinical development for several agents. Premal received BS Pharmacy from Rutgers University; MD and PhD degrees at University of Washington. He completed adult medical oncology fellowship at Memorial Sloan Kettering Cancer Center.